Menu Search
Equities

Sichuan Biokin Pharmaceutical Co Ltd

688506:SHH

Sichuan Biokin Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)195.32
  • Today's Change-5.59 / -2.78%
  • Shares traded1.37m
  • 1 Year change+82.54%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Sichuan Biokin Pharmaceutical Co Ltd's revenues fell -20.11% from 703.28m to 561.87m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 282.38m to a larger loss of 780.50m.
Gross margin95.33%
Net profit margin64.99%
Operating margin70.38%
Return on assets90.79%
Return on equity163.15%
Return on investment138.20%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Sichuan Biokin Pharmaceutical Co Ltd fell by 609.00m. Cash Flow from Financing totalled 90.84m or 16.17% of revenues. In addition the company used 615.35m for operations while cash used for investing totalled 81.88m.
Cash flow per share--
Price/Cash flow per share--
Book value per share10.58
Tangible book value per share10.51
More ▼

Balance sheet in CNYView more

Sichuan Biokin Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 28.07%, a lower figure than the previous year's 37.72%.
Current ratio2.97
Quick ratio2.89
Total debt/total equity0.3902
Total debt/total capital0.2807
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items dropped -176.40%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		785.07
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.